OTTAWA, ONTARIO–(Marketwired – June 15, 2016) – PhytoPain Pharma (PPP) Inc., a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company” or “GCI“) (CSE:GCI), today announced that it has filed a Clinical Trial Application (CTA) with Health Canada for PhytoPain Topical Gel Relief (PPTGR), a locally administered therapeutic for the treatment of chemotherapy-induced neuropathic pain (CINP). Upon approval of the CTA, the Company plans to initiate a double-blind, randomized, cross-over, placebo-controlled clinical study with PPTGR in late 2016 and expects to report initial clinical data from the trial in late 2017.
CINP is a common adverse effect of cancer therapy and a frequent reason why cancer patients stop their treatment early. For some patients, the severity of the symptoms can be reduced by lowering the dose of chemotherapy or temporarily stopping it. In other patients, the symptoms of CINP may last for